医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Otsuka Australia Pharmaceutical Pty Ltd Opens in Australia

2015年01月27日 AM11:00
このエントリーをはてなブックマークに追加


 

TOKYO & SYDNEY

Otsuka Pharmaceutical Co. Ltd, a leading health-related company based in Japan, has established a direct presence in Australia. A new office has been opened in Sydney to bring innovative new medicines to patients in Australia and as a foundation on which to build a larger, long-term presence in Australia and elsewhere in Oceania.

Otsuka is committed to the development of innovative new drugs for central nervous system disorders such as schizophrenia, depression and Alzheimer’s disease, areas where patients in Australia and elsewhere await better treatments. There are an estimated 285,000 people in Australia with schizophrenia, one million with depression and 298,000 with dementia, a significant number of whom have dementia of the Alzheimer’s type.i,ii,iii

The Australian drug market has experienced single-digit percentage growth in the past several years and was estimated at approximately $13 billion (JPY 1.1 trillion or USD 13.6 billion) in 2012, placing it 12th in size in the world.

Otsuka Australia Pharmaceutical’s recently appointed managing director Kazushi Takemoto commented: “Otsuka is pleased and honoured to be a participant in the Australian healthcare sector. We will strive to make a positive contribution with our products in areas of critical, unmet patient need. Our opening in Australia, which is Otsuka’s 27th affiliate outside Japan, is an important milestone for Otsuka as the company continues to expand and fulfil its aim to help ease the burden of diseases on people around the globe.”

About Otsuka Pharmaceutical Co. Ltd

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: ‘Otsuka-people creating new products for better health worldwide.’ Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.

In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and also has research programs for several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.

Otsuka Pharmaceutical is a wholly owned subsidiary of Otsuka Holdings Co. Ltd, Japan’s second-largest drug company. The Otsuka Group employs approximately 42,000 people globally and its products are available in more than 80 countries worldwide.

For more information about Otsuka visit: https://www.otsuka.co.jp/en/
For two short and informative videos about Otsuka, click here: http://www.otsuka.co.jp/en/company/history/

     
i

Fact Sheet on schizophrenia.com. Available at: http://schizophrenia.com/szfacts.htm Accessed on January 13, 2015.

ii

White Cloud Foundation. Available at: http://www.whitecloudfoundation.org/depression-facts Accessed on January 13, 2015.

iii

Australian Institute of Health and Welfare. Dementia in Australia. Press release containing findings available at: http://www.aihw.gov.au/media-release-detail/?id=10737423026 Accessed on January 13, 2015.

CONTACT

For further information please contact:
Otsuka Australia
Pharmaceutical Pty. Ltd
Felicity Moffatt, +61 418677701
Public
Affairs Consultant
felicity@mdmedia.net.au
The
Zenith
Level 20, Tower A
821 Pacific Highway
Chatswood,
2067 NSW

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent